Nexus Biopharma (NEXS) 10-Q 10 Apr 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Nov. 30, 2016	Apr. 06, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	NEXUS BIOPHARMA INC
Entity Central Index Key	1,424,151
Trading Symbol	nexs
Amendment Flag	false
Current Fiscal Year End Date	--02-28
Document Type	10-Q
Document Period End Date	Nov. 30, 2016
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		64,300,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Nov. 30, 2016	Feb. 29, 2016
CURRENT ASSETS
Cash	$ 302	$ 9,925
Sub-lease receivable	8,991
Total Current Assets	9,293	9,925
Furniture and equipment, net	1,632
Intangible asset, net	7,323
TOTAL ASSETS	18,248	9,925
LIABILITIES
Accounts payable and accrued expenses	824,261	735,606
Stock payable	200,000
Note payable	292,500
Total Current Liabilities	1,316,761	735,606
Convertible notes payable - net of unamortized debt discount of $13,888 and 18,889	46,112	41,111
Total Long Term Liabilities	46,112	41,111
TOTAL LIABILITIES	1,362,873	776,717
STOCKHOLDERS' DEFICIT
Common stock, $.001 par value; 750,000,000 shares authorized; 64,309,655 and 31,552,524 shares issued and outstanding, respectively	64,310	31,553
Additional paid-in-capital	1,776,324	1,810,002
Accumulated stockholders' deficit	(3,185,259)	(2,608,347)
Total Stockholders' Deficit	(1,344,625)	(766,792)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 18,248	$ 9,925

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Nov. 30, 2016	Feb. 29, 2016
Statement of Financial Position [Abstract]
Unamortized debt discount	$ 13,888	$ 18,889
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	64,309,655	31,552,524
Common stock, shares outstanding	64,309,655	31,552,524

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2016	Nov. 30, 2015
OPERATING EXPENSES
General and administrative	$ 121,459	$ 51,247	$ 530,875	$ 854,520
Research and development	7,500	107,935	23,904	218,835
Total Operating Expenses	128,959	159,182	554,779	1,073,355
OTHER INCOME (EXPENSE)
Interest expense, net	(8,956)		(22,133)
NET LOSS	$ (137,915)	$ (159,182)	$ (576,912)	$ (1,073,355)
BASIS AND DILUTED NET LOSS PER SHARE	$ 0	$ (0.06)	$ (0.01)	$ (0.42)
WEIGHTED AVERAGE SHARES OUTSTANDING - BASIS AND DILUTED	64,309,656	2,606,524	53,132,560	2,550,426

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Unaudited) - 9 months ended Nov. 30, 2016 - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Feb. 29, 2016	$ (766,792)	$ 31,553	$ 1,810,002	$ (2,608,347)
Balance, Shares at Feb. 29, 2016		31,552,524
Issuance of common stock for services	91,800	$ 4,457	87,343
Issuance of common stock for services, Shares		4,457,132
Cancellation of shares		$ (35,500)	35,500
Cancellation of shares, Shares		(35,500,000)
Adjustment due to the reverse merger	(92,721)	$ 63,800	(156,521)
Adjustment due to the reverse merger, Shares		63,800,000
Net loss	(576,912)			(576,912)
Balance at Nov. 30, 2016	$ (1,344,625)	$ 64,310	$ 1,776,324	$ (3,185,259)
Balance, Shares at Nov. 30, 2016		64,309,656

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Nov. 30, 2016	Nov. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (576,912)	$ (1,073,355)
Adjustments to reconcile net loss to net cash used by operating activities
Amortization of debt discount	5,001
Depreciation and Amortization expense	984
Stock based compensation	91,800	625,000
Change in operating assets and liabilities
Sub-lease receivable	(8,991)
Accounts payable and accrued expenses	(4,066)	426,303
NET CASH USED IN OPERATING ACTIVITIES	(492,184)	(22,052)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for furniture and equipment	(1,689)
Cash paid for website development costs	(8,250)
NET CASH USED IN INVESTING ACTIVITIES	(9,939)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable	292,500
Proceeds from equity line of credit	200,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	492,500
NET DECREASE IN CASH	(9,623)	(22,052)
Cash at the beginning of the period	9,925	22,052
Cash at the end of the period	302
SUPPLEMENTAL DISCLOSURES:
Interest paid
Income taxes paid
NON CASH TRANSACTIONS
Cancellation of shares	35,500
Adjustment due to the reverse merger	$ 92,721

Nature of Operations and Going

Nature of Operations and Going Concern	9 Months Ended
	Nov. 30, 2016
Nature of Operations and Going Concern [Abstract]
NATURE OF OPERATIONS AND GOING CONCERN	NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN Nexus BioPharma, Inc. (”we”, “our”, “NBP”, “the Company”) was incorporated in Delaware on April 17, 2013. During this time the Company devoted substantially all of its efforts to activities such as financial planning and raising capital. The Company did not have any transactions from incorporation date through the period ended February 28, 2014. NBP is a life science company focused on the development and commercialization of a pharmaceutical preparation to treat obesity and the symptoms of type 2 diabetes. On February 1, 2016, the Company effected a 1 for 13.5 reverse stock split of its common stock. All share information in the financial statements for fiscal years 2016 and 2015 reflect the impact of the reverse stock split. Reverse merger On May 17, 2016 the Company entered into an Agreement and Plan of Reorganization (“Merger Agreement”) by and among Nexus Bio Pharma, Inc. a Nevada corporation (“Nexus”), the Company and Nexus Acquisition Corp. (“Acquisition Corp.”), a Delaware corporation and wholly owned subsidiary of Nexus. The Merger Agreement closed on June 9, 2016 and resulted in the following: Acquisition Corp. merged with the Company with the latter as the surviving company in the merger. The Company shall continue its corporate existence under the name “Nexus Biopharma, Inc.” Each share of common stock of the Company prior to the merger converted into 4.8552632 shares of common stock, par value $0.001 per share, of Nexus. Nexus then cancelled 35,500,000 shares of its common stock that were outstanding prior to the merger. The Company’s stockholders shall receive convertible promissory notes corresponding to their proportional ownership interest of NBP common stock which shall be convertible into newly created shares of preferred stock of Nexus. The Nexus preferred shares shall be convertible into 36,000,000 shares of Nexus common stock. The convertible notes will be issued once Nexus has the preferred shares in place. The transaction is accounted for as a reverse acquisition and the Company is considered the accounting acquirer for financial reporting purposes. The historical consolidated financial statements include the operations of the accounting acquirer for all periods presented. Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial statements. Accordingly, such interim financial statements do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete annual financial statements. The information furnished reflects all adjustments, consisting only of normal recurring items which are, in the opinion of management, necessary in order to make the financial statements not misleading. The balance sheet as of February 29, 2016 has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm, but does not include all of the information and footnotes required for complete annual financial statements. The financial statements included in this Quarterly Report should be read in conjunction with the financial statements and the notes thereto included in the Company’s Report on Form 8-K filed on June 15, 2016. Going Concern These financial statements have been prepared on a going concern basis. The Company has incurred losses since inception and has a working capital deficit, which raises substantial doubt about The Company’s ability to continue as a going concern. Its ability to continue as a going concern is dependent upon the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through a private placement and public offering of its common stock. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence.

License Agreement and Commitmen

License Agreement and Commitments	9 Months Ended
	Nov. 30, 2016
License Agreement and Commitments [Abstract]
LICENSE AGREEMENT AND COMMITMENTS	NOTE 2 – LICENSE AGREEMENT AND COMMITMENTS The Company entered in to a Patent and Technology License Agreement with the Albert Einstein College of Medicine (Licensors) in March 2014. The agreement grants the Company a world-wide exclusive license to materials and methods for use in the diagnosis and treatment of cancers, obesity and diabetes with inhibitors of Fyn kinase. In return the Company has agreed a license fee to Licensors, to reimburse licensors patent expenses thus far incurred, to pay all future patent expenses, pay a royalty on any sales of product using licensed technology, as well as certain minimum royalties and milestone payments. Pursuant to the License Agreement, we are also obligated to make the following royalties and payments to the Licensors: · Royalty payment equivalent to 3% of net sales. · Royalty payment of minimum of a specified percentage of net sales in case the Company pays royalties to unaffiliated third parties for patent rights. · Pay 20% of any net proceeds that the Company will receive pursuant to a sublicense agreement that the Company will enter into with other parties. · Issue 30% of the Company outstanding common stock to the Licensors calculated on a fully diluted, as converted basis. Accordingly, we issued 126,984 common shares valued at $857,143 which was charged to research and development expense in the statements of operations. · Non-refundable license fee of $25,000 upon execution of License Agreement. · License maintenance fee of $30,000 on each of the first, second, third and fourth anniversary of the License Agreement. The payment may be credited against royalties made during the twelve month period. · License maintenance fee of $50,000, and $75,000 on the fifth and sixth anniversaries of the License Agreement, respectively. Each payment may be credited against royalties made during each such twelve month period. · License maintenance fee of $100,000 on the seventh and each subsequent anniversary of the License Agreement. Each payment may be credited against royalties made during each such twelve month period. · Milestone payments ranging from $100,000 to $750,000 if certain milestones are achieved. Additionally, under the license agreement the Company is obligated to offer new shares to the licensors on a fully diluted basis for all new stock issues with the sale terms offered under the new issue. The License Agreement will terminate upon expiration of the patent. The initial payment of $30,000, due March 3, 2015 was not made and the second annual payment, due March 3, 2016 was not made. As of the date of this filing the Company has not received any demand for payment or notice of default from Albert Einstein College of Medicine. The Company plans to pay these minimum royalty payments as soon as adequate funds are available.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Nov. 30, 2016
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 3—RELATED PARTY TRANSACTIONS The Company has an employment agreement with the principal officer and stockholder providing for a base salary of $43,750 and $131,250 in the three and nine months ended November 30, 2016, respectively and $36,250 and $108,750 in the three months and nine ended November 30, 2015, respectively. The base salary shall be increased at the end of each year to reflect the change in the consumer price index and the board of directors may award increases in the base salary greater than those provided above. If the officer continues active employment after 2016, compensation will be negotiated. The Company’s obligation under the employment agreement accrues only as the service is rendered. As of November 30, 2016 and February 29, 2016, unpaid salaries to the CEO amounted to $181,472 and $193,915, respectively. On March 1, 2014, the Company entered into a consulting agreement with a principal stockholder providing monthly payments of $5,000 plus reimbursable travel expenses for a period of six months, after which, the agreement shall automatically renew for an additional three month term unless terminated by either party with 15 day prior notice. On June 1, 2014, the Company entered into a new agreement with the principal stockholder with the same terms as the previous one except that the monthly fee was increased to $7,500. Total consulting fees incurred for the three months and nine months ended November 30, 2016 amounted to $22,500 and $52,500 respectively. For the three months and nine months ended November 30, 2015 no services were rendered under the agreement; and therefore, no consulting fee expense was recorded.

Short Term Debt

Short Term Debt	9 Months Ended
	Nov. 30, 2016
Short Term Debt and Convertible Notes Payable [Abstract]
SHORT TERM DEBT	NOTE 4 – SHORT TERM DEBT Short term notes payable consist of an unsecured note payable of $292,500 with an interest rate of 10% and is due in April 2017.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Nov. 30, 2016
Short Term Debt and Convertible Notes Payable [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 5 – CONVERTIBLE NOTES PAYABLE Convertible notes were issued during December 2015 and January 2016 with principal amounts totaling to $60,000. The notes are non-interest bearing and have a term of three years. The notes were contemplated to automatically convert into the Company’s planned units offering with each unit consisting of two shares of common stock and one warrant at a price of $1 per unit. An aggregate of 60,000 warrants were issued with the notes. These warrants have an exercise price of $1.50 per share and a term of 3 years. The relative fair value of the warrants amounting to $20,000 was recognized as a debt discount and amortized over the term of the notes. Amortization expense for the three and nine months ended November 30, 2016 was $1,667 and $5,001, respectively.

Equity

Equity	9 Months Ended
	Nov. 30, 2016
Equity [Abstract]
EQUITY	NOTE 6 – EQUITY Shares for service Subsequent to February 29, 2016, the Company issued 4,457,132 (post-merger) shares of common stock for consulting services with a fair value of $91,800. Equity Line of Credit The Company entered into an Equity Line of Credit Agreement (the “ELOC”) with Corelli Capital A.G. (“CCAG”) on June 14, 2016. The terms of the agreement provide that the Company shall issue and sell to CCAG up to $2,250,000 of the Company’s common stock. The Company can request in separate transactions a maximum advance amount of $200,000 in exchange for the issuance of the equivalent amount of common stock valued at the current market price. The first advance amount will be calculated at $0.20 per share. The agreement will expire, either seven months from the agreement date or, when the investor shall have made the payment of advances totaling $2,250,000, whichever comes first. The Company requested an advance for $200,000 on June 22, 2016 of which $100,000 was received as of August 31, 2016 and the remaining $100,000 was received on September 7, 2016. Under the terms of the ELOC the Company will issue 1,000,000 shares in return for the first funding of $200,000, but as of November 30, 2016 the 1,000,000 share have not been issued. As of January 14, 2017 the equity line of credit agreement has expired. Warrants As of November 30, 2016, the Company has an aggregate of 60,000 warrants outstanding and exercisable with a weighted average exercise price of $1.50 and a weighted average remaining term of 2.15 years.

Leases

Leases	9 Months Ended
	Nov. 30, 2016
Leases [Abstract]
LEASES	NOTE 7 –LEASES The Company leases its New Jersey facilities under an operating lease. This lease, which terminates on July 31 2017, requires monthly payments of $6,491. The lease can be terminated with notice given at least ninety days prior to the intended date of termination. The Company is also obligated to pay additional rent to cover the lessee’s share of taxes and operating costs in excess of specified base amounts. Rent expense for the three and nine months ended November 30, 2016 were $17,873 and $24,447, respectively. Additionally, the Company has sub-leased a portion of its office space under two agreements. The first sub-lease, which terminates on July 31 2017, requires monthly payments of $2,164. The lease can be terminated with notice given at least sixty days prior to the intended date of termination. The second sub-lease, which terminates on July 31 2017, requires monthly payments of $2,500. The lease can be terminated with notice given at least ninety days prior to the intended date of termination. The Company has recorded the rent collected or accrued under the sub-leases as a reduction of rent expense. Rent expense and sublease rentals for both the three and nine months ended November 30, 2016 amounted to $24,447 and $18,655, respectively. The Company has executed a new operating lease on November 18, 2016 for facilities in Houston, Texas to begin February 1, 2017. This lease, which terminates on December 31, 2017, requires monthly payments of $500. Future minimum lease payments and sublease rentals under the aforementioned operating leases are as follows: Year ended February 28, Rent Sublease rentals 2017 $ 19,974 $ 13,991 2018 $ 37,457 $ 23,319

Nature of Operations and Goin14

Nature of Operations and Going Concern (Policies)	9 Months Ended
	Nov. 30, 2016
Nature of Operations and Going Concern [Abstract]
Reverse merger	Reverse merger On May 17, 2016 the Company entered into an Agreement and Plan of Reorganization (“Merger Agreement”) by and among Nexus Bio Pharma, Inc. a Nevada corporation (“Nexus”), the Company and Nexus Acquisition Corp. (“Acquisition Corp.”), a Delaware corporation and wholly owned subsidiary of Nexus. The Merger Agreement closed on June 9, 2016 and resulted in the following: Acquisition Corp. merged with the Company with the latter as the surviving company in the merger. The Company shall continue its corporate existence under the name “Nexus Biopharma, Inc.” Each share of common stock of the Company prior to the merger converted into 4.8552632 shares of common stock, par value $0.001 per share, of Nexus. Nexus then cancelled 35,500,000 shares of its common stock that were outstanding prior to the merger. The Company’s stockholders shall receive convertible promissory notes corresponding to their proportional ownership interest of NBP common stock which shall be convertible into newly created shares of preferred stock of Nexus. The Nexus preferred shares shall be convertible into 36,000,000 shares of Nexus common stock. The convertible notes will be issued once Nexus has the preferred shares in place. The transaction is accounted for as a reverse acquisition and the Company is considered the accounting acquirer for financial reporting purposes. The historical consolidated financial statements include the operations of the accounting acquirer for all periods presented.
Basis of Presentation	Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial statements. Accordingly, such interim financial statements do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete annual financial statements. The information furnished reflects all adjustments, consisting only of normal recurring items which are, in the opinion of management, necessary in order to make the financial statements not misleading. The balance sheet as of February 29, 2016 has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm, but does not include all of the information and footnotes required for complete annual financial statements. The financial statements included in this Quarterly Report should be read in conjunction with the financial statements and the notes thereto included in the Company’s Report on Form 8-K filed on June 15, 2016.
Going Concern	Going Concern These financial statements have been prepared on a going concern basis. The Company has incurred losses since inception and has a working capital deficit, which raises substantial doubt about The Company’s ability to continue as a going concern. Its ability to continue as a going concern is dependent upon the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through a private placement and public offering of its common stock. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence

Leases (Tables)

Leases (Tables)	9 Months Ended
	Nov. 30, 2016
Leases [Abstract]
Schedule of future minimum lease payments and sublease rentals	Year ended February 28, Rent Sublease rentals 2017 $ 19,974 $ 13,991 2018 $ 37,457 $ 23,319

Nature of Operations and Goin16

Nature of Operations and Going Concern (Details) - $ / shares	Jun. 09, 2016	Feb. 01, 2016
Nature of Operations and Going Concern (Textual)
Reverse stock split		1 for 13.5 reverse stock split
Merger Agreement [Member]
Nature of Operations and Going Concern (Textual)
Converted into shares of common stock	4.8552632
Merger Agreement [Member] | Nevada Corporation [Member]
Nature of Operations and Going Concern (Textual)
Converted into shares of common stock	36,000,000
Shares issued, price per share	$ 0.001
Cancelled shares of common stock	35,500,000

License Agreement and Commitm17

License Agreement and Commitments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2016	Nov. 30, 2015
License Agreement and Commitments (Textual)
Royalty payment percentage	3.00%		3.00%
Percentage of net proceeds to other parties			20.00%
Outstanding of common stock diluted percentage			30.00%
Research and development expense	$ 7,500	$ 107,935	$ 23,904	$ 218,835
Initial payment of license costs			$ 30,000
License settlement agreement terms			The initial payment of $30,000, due March 3, 2015 was not made and the second annual payment, due March 3, 2016 was not made.
Minimum [Member]
License Agreement and Commitments (Textual)
Milestone payments	100,000		$ 100,000
Maximum [Member]
License Agreement and Commitments (Textual)
Milestone payments	750,000		750,000
License Agreement [Member]
License Agreement and Commitments (Textual)
Research and development expense			$ 857,143
Issued of common stock shares			126,984
Non - refundable license fees			$ 25,000
First Anniversary License Agreement [Member]
License Agreement and Commitments (Textual)
License maintenance fees	30,000		30,000
Second Anniversary License Agreement [Member]
License Agreement and Commitments (Textual)
License maintenance fees	30,000		30,000
Third Anniversary License Agreement[Member]
License Agreement and Commitments (Textual)
License maintenance fees	30,000		30,000
Fourth Anniversary License Agreement [Member]
License Agreement and Commitments (Textual)
License maintenance fees	30,000		30,000
Fifth Anniversary License Agreement [Member]
License Agreement and Commitments (Textual)
License maintenance fees	50,000		50,000
Sixth Anniversary License Agreement [Member]
License Agreement and Commitments (Textual)
License maintenance fees	75,000		75,000
Seventh Anniversary License Agreement [Member]
License Agreement and Commitments (Textual)
License maintenance fees	$ 100,000		$ 100,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2016	Nov. 30, 2015	Feb. 29, 2016
Related Party Transactions (Textual)
Base salary amount	$ 43,750	$ 36,250	$ 131,250	$ 108,750
Related party transaction, description			On March 1, 2014, the Company entered into a consulting agreement with a principal stockholder providing monthly payments of $5,000 plus reimbursable travel expenses for a period of six months, after which, the agreement shall automatically renew for an additional three month term unless terminated by either party with 15 day prior notice. On June 1, 2014, the Company entered into a new agreement with the principal stockholder with the same terms as the previous one except that the monthly fee was increased to $7,500.
Consulting fees	$ 22,500		$ 52,500
Chief Executive Officer [Member]
Related Party Transactions (Textual)
Unpaid salaries			$ 181,472		$ 193,915

Short Term Debt (Details)

Short Term Debt (Details)	9 Months Ended
	Nov. 30, 2016USD ($)
Short Term Debt (Textual)
Unsecured note payable	$ 292,500
interest rate	10.00%
Maturity date	Apr. 30, 2017

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	3 Months Ended	9 Months Ended
	Nov. 30, 2016	Nov. 30, 2016	Jan. 31, 2016	Dec. 31, 2015
Convertible Notes Payable (Textual)
Principal amount			$ 60,000	$ 60,000
Debt conversion, description		The notes are non-interest bearing and have a term of three years. The notes were contemplated to automatically convert into the Company's planned units offering with each unit consisting of two shares of common stock and one warrant at a price of $1 per unit.
Warrants issued		60,000
Warrants exercise price per share	$ 1.50	$ 1.50
Warrants term		3 years
Fair value of warrants		$ 20,000
Amortization expense	$ 1,667	$ 5,001

Equity (Details)

Equity (Details) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 29, 2016	Nov. 30, 2016
Equity (Textual)
Issuance of common stock for services		$ 91,800
Warrants outstanding		60,000
Warrants exercise price per share		$ 1.50
Term of warrants		2 years 1 month 24 days
Equity Line of Credit Agreement [Member]
Equity (Textual)
Line of credit facility, description		The terms of the agreement provide that the Company shall issue and sell to CCAG up to $2,250,000 of the Company's common stock. The Company can request in separate transactions a maximum advance amount of $200,000 in exchange for the issuance of the equivalent amount of common stock valued at the current market price. The first advance amount will be calculated at $0.20 per share. The agreement will expire, either seven months from the agreement date or, when the investor shall have made the payment of advances totaling $2,250,000, whichever comes first. The Company requested an advance for $200,000 on June 22, 2016 of which $100,000 was received as of August 31, 2016 and the remaining $100,000 was received on September 7, 2016. Under the terms of the ELOC the Company will issue 1,000,000 shares in return for the first funding of $200,000, but as of November 30, 2016 the 1,000,000 share have not been issued.
Consulting Services [Member]
Equity (Textual)
Issuance of common stock for services, Shares	4,457,132
Issuance of common stock for services	$ 91,800

Leases (Details)

Leases (Details)	Nov. 30, 2016USD ($)
Leases [Abstract]
Operating leases, Rent, 2017	$ 19,974
Operating leases, Rent, 2018	37,457
Operating leases, Sublease rentals, 2017	13,991
Operating leases, Sublease rentals, 2018	$ 23,319

Leases (Details Textual)

Leases (Details Textual)	3 Months Ended	9 Months Ended
	Nov. 30, 2016USD ($)	Nov. 30, 2016USD ($)Agreements
Leases (Textual)
Rent expense	$ 24,447	$ 18,655
Sublease rentals	24,447	$ 18,655
Number of agreements | Agreements		2
New Jersey facilities [Member]
Leases (Textual)
Lease terminates date		Jul. 31, 2017
Monthly payments of operating lease		$ 6,491
Lease date of termination description		The lease can be terminated with notice given at least ninety days prior to the intended date of termination.
Rent expense	$ 17,873	$ 24,447
First sub-lease [Member]
Leases (Textual)
Lease terminates date		Jul. 31, 2017
Monthly payments of operating lease		$ 2,164
Lease date of termination description		The lease can be terminated with notice given at least sixty days prior to the intended date of termination.
Second sub-lease
Leases (Textual)
Lease terminates date		Jul. 31, 2017
Monthly payments of operating lease		$ 2,500
Lease date of termination description		The lease can be terminated with notice given at least ninety days prior to the intended date of termination.
Houston [Member]
Leases (Textual)
Lease terminates date		Dec. 31, 2017
Monthly payments of operating lease		$ 500